USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
https://doi.org/10.14412/1996-7012-2010-588
Abstract
Clinical trials have provided evidence for the efficacy of tocilizumab (TCZ) used alone and in combination with basic anti-inflammatory drugs
in patients with rheumatoid arthritis (RA). TCZ therapy has been found to considerably alleviate the clinical manifestations of RA, improves
joint function and quality of life, and retards joint destruction and radiographic disease progression. TCZ has been noted to demonstrate good
results in the treatment of patients with the prolonged disease and a history of inefficient tumor necrosis factor-〈 inhibitors.
in patients with rheumatoid arthritis (RA). TCZ therapy has been found to considerably alleviate the clinical manifestations of RA, improves
joint function and quality of life, and retards joint destruction and radiographic disease progression. TCZ has been noted to demonstrate good
results in the treatment of patients with the prolonged disease and a history of inefficient tumor necrosis factor-〈 inhibitors.
References
1. <div><p>Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М., ГЭОТАР-Медиа, 2008;290-331.</p><p>Smolen A., Rubbert-Roth A., Ramos-Remus C. et al. Effect of interleukin-6 receptor ingibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomased trial. Lancet 2008;371:907-13.</p><p>Насонов Е.Л. Применение тоцилизумаба (Актемры) при ревматоидном артрите. Науч-практич ревматол 2009;3(прил.):18-34.</p><p>Nishimoto N., Hashimoto J., Miyasaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader- blinded randomised controlled trial of tocilizumab. Ann Rheu Dis 2007;66:1162-7.</p><p>Furst D.E., Keystone E.C., Fleischmann R. et al. Update consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010;69(Suppl. I):i2-i29.</p><p>Nishimoto N., Miyasaka N., Yamanaka K. et al. Safety profile of tocilizumab in Japanise patients with rheumatoid arthritis - incidences of infections in Japanise long-term clinical studies. Ann Rheum Dis 2008;67(Suppl. II):335. 7.</p><p>European Medicines Agency. RoActemra (tocilizumab): summary of product characteristics. Available from URL: http://www.emea.europa.eu/humandocs/PD Fs/EPAR/RoActemra/H-955-PI-en.pdf (Accessed 2009 Mar23).</p></div><br />
Review
For citations:
Nasonov EL, Panasyuk EY, Nasonov EL, Panasyuk EY. USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2010;4(1):59-61. (In Russ.) https://doi.org/10.14412/1996-7012-2010-588
Views:
1462
Email this article 